8sta

Prevention of brain decline: generic and individual factors influencing benefit from nutrition, physical and mental activity and lifestyle interventions

Acronym : PrecisePrevent

Call : NutriBrain 2024

logo

Topic

The main aim of PrecisePrevent is to contribute knowledge about how brain aging can be ameliorated through low-cost, easily accessible non-pharmacological means. There are large individual differences in response to interventions, and a crucial question regards who benefits the most from what? We will test the associations between lifestyle factors, including nutrition, sleep, physical and cognitive activity, and brain health in aging. We will leverage retrospective large-scale longitudinal brain imaging studies combined with mega-analysis of seven experimental brain health interventions. General and specific factors for individuals and interventions will be systematically mapped.

The results will be implemented in a digital personalized intervention run across four countries. This allows us directly to test how much brain aging and cognitive function can be affected by lifestyle changes, and which variables that contribute to promote or restrict the effects. We will systematically estimate how much benefits can be optimized using genetic and non-genetic factors to generate individual-level predictors and intervention targets. As lifestyle changes are difficult to sustain, we will, working with stakeholders and target-groups, develop a personalized intervention which allows participants to select their own targets and evaluate predicted effects on brain health. Machine learning will be used to optimize the cost-benefit balance. The personalized intervention programs will be delivered and assessed through an interactive mobileHealth platform, which we already have preliminary validated. This enables us to determine the increase in benefits from personalized vs. general intervention approaches. The aim is to develop a framework for a scalable low-threshold intervention feasible at a pan-European level. The rationale is that aggregation of modest individual benefits will result in substantial societal advantages.

  • Coordinator:
    • Kristine WALHOVD, University of Oslo, Norway
  • Partners:
    • Gaël CHETELAT, National Institute of Health and Medical Research (INSERM), France;
    •  Emrah DUEZEL, The German Center for Neurodegenerative Diseases (DZNE), Germany;
    •  Antoni SISÓ ALMIRALL, The Clinic Foundation for Biomedical Research-August Pi Sunyer Biomedical Research Institute (FRCB-IDIBAPS), Spain;
    • Javier SOLANA-SÁNCHEZ, Institute Guttmann, Spain
  • Collaborators:
    • (*) Alvaro PASCUAL-LEONE, Harvard Medical School, United States
Back to index